GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Asset Turnover

Helix BioPharma (TSX:HBP) Asset Turnover : 0.00 (As of Jan. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Helix BioPharma's Revenue for the three months ended in Jan. 2025 was C$0.00 Mil. Helix BioPharma's Total Assets for the quarter that ended in Jan. 2025 was C$1.33 Mil. Therefore, Helix BioPharma's Asset Turnover for the quarter that ended in Jan. 2025 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Helix BioPharma's annualized ROE % for the quarter that ended in Jan. 2025 was 795.37%. It is also linked to ROA % through Du Pont Formula. Helix BioPharma's annualized ROA % for the quarter that ended in Jan. 2025 was -414.16%.


Helix BioPharma Asset Turnover Historical Data

The historical data trend for Helix BioPharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Asset Turnover Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Helix BioPharma's Asset Turnover

For the Biotechnology subindustry, Helix BioPharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Asset Turnover falls into.


;
;

Helix BioPharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Helix BioPharma's Asset Turnover for the fiscal year that ended in Jul. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jul. 2024 )/( (Total Assets (A: Jul. 2023 )+Total Assets (A: Jul. 2024 ))/ count )
=0/( (1.029+1.489)/ 2 )
=0/1.259
=0.00

Helix BioPharma's Asset Turnover for the quarter that ended in Jan. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jan. 2025 )/( (Total Assets (Q: Oct. 2024 )+Total Assets (Q: Jan. 2025 ))/ count )
=0/( (0.414+2.242)/ 2 )
=0/1.328
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Helix BioPharma  (TSX:HBP) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Helix BioPharma's annulized ROE % for the quarter that ended in Jan. 2025 is

ROE %**(Q: Jan. 2025 )
=Net Income/Total Stockholders Equity
=-5.5/-0.6915
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-5.5 / 0)*(0 / 1.328)*(1.328/ -0.6915)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-1.9205
=ROA %*Equity Multiplier
=-414.16 %*-1.9205
=795.37 %

Note: The Net Income data used here is four times the quarterly (Jan. 2025) net income data. The Revenue data used here is four times the quarterly (Jan. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Helix BioPharma's annulized ROA % for the quarter that ended in Jan. 2025 is

ROA %(Q: Jan. 2025 )
=Net Income/Total Assets
=-5.5/1.328
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-5.5 / 0)*(0 / 1.328)
=Net Margin %*Asset Turnover
= %*0
=-414.16 %

Note: The Net Income data used here is four times the quarterly (Jan. 2025) net income data. The Revenue data used here is four times the quarterly (Jan. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Helix BioPharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.